How Clinevo Detects Safety Signals Other Platforms Miss

 The global spontaneous reporting system now spans databases of extraordinary scale. FAERS alone holds 31.8 million records,EudraVigilance contained over 29.3 million ICSRs as of early 2024,and in early 2025, WHO VigiBase crossed 40 million reports. FAERS alone receives over two million new adverse event and medication error reports every year.



Yet volume, in isolation, does not guarantee that every true signal surfaces in time. In 2025,EMA’s signal management team reviewed 1,201 potential safety signals across 995 active substances. Beyond data availability, the real challenge lies in whether a platform can extract genuine signals from the volume without generating a workload of false positives that consumes the time safety teams need for real investigation.

Most pharmacovigilance platforms approach drug safety signal detection through a narrow statistical lens: a standard disproportionality analysis run on spontaneous reports from a single database, queried at fixed intervals. This is a starting point, not a complete methodology. Signals that require cross-database context, temporal pattern analysis, or upstream data from case intake and literature review remain invisible to platforms not designed to integrate these inputs.

This article examines where conventional signal detection methods fall short, what the structural gaps look like at each stage of the signal lifecycle, and how the Clinevo Signal Management Platform is built to close them.
READ MORE

Comments

Post a Comment

Popular posts from this blog

From First Contact to Case Record: AI-Powered Pharmacovigilance Intake with AWS Connect

Image
  Drug safety hotlines have operated the same way for decades. An agent picks up a call, listens, and types what they hear into a case management system. When the call ends, they review their notes, fill in gaps, and route the case for medical review. It is a process built on human attention and manual transcription — and it has not fundamentally changed since PV call centres first came into existence. The volume of adverse event reports, however, has increased. Global drug portfolios now generate case volumes growing to 20% annually. A serious adverse event reported at 11 PM in one time zone triggers regulatory obligations that don’t wait for business hours in another. And a missed or inaccurately transcribed seriousness criterion can have consequences that reach from the case record all the way to a regulatory inspection. This is the operational context in which AWS Connect telephony for pharmacovigilance is gaining serious attention from drug safety teams. Not as a replacement f...
Read more

From Literature Noise to Actionable Insights: Automating End-to-End Surveillance

Image
  Every week, a pharmacovigilance team opens their literature monitoring queue to find hundreds of articles pulled from PubMed, EMBASE, and regional databases. The majority of these articles are often duplicates, off-label mentions, or pharmacokinetic studies that lack any meaningful adverse event content, adding unnecessary noise to the process.  This is precisely the problem that  AI literature management  is designed to solve — not by adding another layer of retrieval, but by bringing intelligence into every stage of the workflow. The EMA’s own 2024 Annual Report on EudraVigilance puts this problem in clear numbers. In 2024, the agency reviewed 1,254 potential safety signals. Of those, 76% were not validated and closed. Only 3.1%, were ultimately prioritised and assessed by PRAC.  That ratio reflects a broader industry challenge: when literature monitoring generates excessive noise upstream, safety teams spend more time triaging irrelevant content than evalua...
Read more

Beyond Case Counting: How AI Is Transforming Aggregate Safety Reporting.

Image
  Every six months, or annually depending on the product’s EU reference date (EURD) schedule, pharmacovigilance teams begin assembling one of the most resource-intensive documents in drug safety: the Periodic Benefit-Risk Evaluation Report (PBRER), or its regulatory counterpart, the Periodic Safety Update Report (PSUR). The process typically starts at least two to four months before the submission deadline and involves medical writers, pharmacovigilance scientists, signal detection specialists, regulatory affairs teams, and clinical reviewers working simultaneously across disconnected systems. The challenge is not the report itself. The challenge is everything that has to happen before the first section can be written. Signal data has to be extracted, verified, and reconciled. ICSR line listings have to be built. Cumulative case counts have to be validated against database outputs. And all of this has to be ready before the data lock point, with no room for error, because the submi...
Read more